Early implementation of long-acting injectable cabotegravir for HIV prevention in a safety net hospital-based primary care center in U.S. South.
Baker D, Collins LF, Cantos VD, et al. J Gen Intern Med. 2026;41(1):43-52.
Direct initiation of long-acting cabotegravir plus rilpivirine in people with HIV and suboptimal virologic suppression: a randomized trial.
Chen N-Y, Chen C-P, Lin Y-C, et al. Clin Infect Dis. 2026:ciag504.
Exploring workflows for long-acting antiretroviral therapy administration in community pharmacies.
Clinard V, Bumanglag K, Saberi P, et al. J Am Pharm Assoc. 2026;66(1):102979.
Long-acting cabotegravir injections are more acceptable than long-acting lenacapavir injections after one dose: results from the CLARITY randomized crossover study.
Elliot ER, Boles J, Fox D, et al. Adv Ther. 2026.
Long-acting HIV pre-exposure prophylaxis adherence and discontinuation: a global systematic review and meta-analysis.
Feng X, Wu X, Fitzpatrick TS, et al. EClinicalMedicine. 2026;99:104189.
Long-acting lenacapavir and cabotegravir and viral suppression among people with HIV.
Gistand NL, Mishra IC, Hunter K, et al. JAMA Netw Open. 2026. [Epub ahead of print]
Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years.
Margot NA, Jogiraju V, Pennetzdorfer N, et al. J Infect Dis. 2025;231(5):1239-1245.
Subcutaneous lenacapavir in people with multidrug-resistant HIV-1: 156 week results of the CAPELLA study.
Ogbuagu O, Wiznia A, McGowan JP, et al. Open Forum Infect Dis. 2025;13(1):ofaf763.
High retention and adherence with rapid long-acting injectable preexposure prophylaxis implementation in an urban safety net clinic population.
Spinelli MA, Bisom-Rapp E, Heise MJ, et al. Clin Infect Dis. 2025;80(5):1139-1142.
Virologic outcomes after LA ART initiation with and without viremia in two large U.S. clinic cohorts.
Spinelli M, Heise MJ, Glidden DV, et al. Clin Infect Dis. 2026:ciag392.
Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: a systematic review and meta-analysis.
Tieosapjaroen W, Williams E, Johnson CC, et al. PLoS Med. 2026;23(4):e1005030.
CLINICAL PRACTICE GUIDELINES
Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel.
Gandhi RT, Landovitz RJ, Sax PE, et al. JAMA. 2025;333(7):609-628.
Preexposure prophylaxis for HIV: updated recommendations from the 2024 International Antiviral Society-USA Panel.
Landovitz RJ, et al. JAMA. 2025;334(7):638-639.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services.
CLINICIAN RESOURCES
Cabotegravir.
HIV.gov. Drug database.
Cabotegravir/Rilpivirine.
HIV.gov. Drug database.
Lenacapavir.
HIV.gov. Drug database.
Clinical Guidelines Program: HIV Treatment.
New York State Department of Health AIDS Institute.
Clinician-to-Clinician Advice.
National Clinician Consultation Center; University of California, San Francisco.
HIV Drug Resistance Database.
Stanford University.
HIV drug interactions.
University of Liverpool.
PATIENT AND CAREGIVER RESOURCES
AIDSMap.
NAM Publications.
Living With HIV.
Centers for Disease Control and Prevention.
Public HIV resources.
National Institutes of Health.
22
2026
LIVE: Optimizing Outcomes with LAI PrEP and ART
Advanced Clinical Decision Making in HIV Care
| Time: | 6:30 PM-8:30 PM ET |
| Venue: | ID Week - Marriott Marquis Salon 6 |
| Location: | Washington, DC |
| Faculty: | Monica Gandhi, MD, MPH; Paul E. Sax, MD; Meredith E. Clement, MD, MHSc |
22
2026
VIRTUAL: Optimizing Outcomes with LAI PrEP and ART
Advanced Clinical Decision Making in HIV Care
| Time: | 6:30 PM-8:30 PM ET |
| Venue: | Online - Virtual Live Stream |
| Location: | Online - Virtual Live Stream |
| Faculty: | Monica Gandhi, MD, MPH; Paul E. Sax, MD; Meredith E. Clement, MD, MHSc |
